A Relationship Between Serotonin Transporter Genotype and in Vivo Protein Expression and Alcohol Neurotoxicity
Overview
Affiliations
Background: Genetic variation of the promoter for the serotonin transporter (5-HTT) gene has been associated with its functional capacity. In vitro, carriers of a short allele (s-carriers) of the 5-HTT promoter display significant reduction in 5-HTT capacity. Dysfunction of 5-HTT has been observed in alcoholic individuals. We assessed whether the allelic constitution of the 5-HTT gene is associated with reduced serotonin transporter availability among alcoholic individuals.
Methods: We genotyped the 5-HTT promoter region and measured the availability of serotonin transporter protein with [I-123]beta-CIT SPECT in the raphe area in 14 abstinent male alcoholic subjects and 8 age-matched control subjects of European American descent.
Results: Among control subjects, the ratio of in vivo 5-HTT availability for ll-homozygous individuals relative to s-carriers was comparable to serotonin uptake ratios measured in vitro. There was a significant interaction of diagnosis and 5-HTT promoter genotype on 5-HTT availability (p <.01). Among controls, ll-homozygous individuals displayed a significant increase as compared with s-carriers. The availability of raphe 5-HTT was significantly reduced in ll-homozygous alcoholic individuals and was negatively correlated with their amount of alcohol consumption. Among s-carriers, 5-HTT availability did not differ significantly between control and alcoholic subjects.
Conclusions: Our preliminary findings suggest an association between 5-HTT allelic constitution and in vivo measurements of human serotonin transporter availability, and a potentially selective susceptibility of ll-homozygous individuals to the neurotoxic effects of chronic excessive alcohol consumption.
Castle M, Flanigan M Neurobiol Stress. 2024; 30:100618.
PMID: 38433994 PMC: 10907856. DOI: 10.1016/j.ynstr.2024.100618.
Neurotoxicology of alcohol: a bibliometric and science mapping analysis.
Mendes P, Baia-da-Silva D, Melo W, Bittencourt L, Souza-Rodrigues R, Fernandes L Front Pharmacol. 2023; 14:1209616.
PMID: 37593178 PMC: 10427875. DOI: 10.3389/fphar.2023.1209616.
Wilkinson A, Swann A, Graham D, Patriquin M, Salas R, Nielsen D J Affect Disord. 2022; 311:631-636.
PMID: 35623482 PMC: 9842073. DOI: 10.1016/j.jad.2022.05.114.
Sarkar S, Singh R, Sharma A, Pandit M, Gupta R, Singhal D Cureus. 2021; 13(11):e19310.
PMID: 34900485 PMC: 8647861. DOI: 10.7759/cureus.19310.
Beversdorf D, Shah A, Jhin A, Noel-MacDonnell J, Hecht P, Ferguson B Front Psychiatry. 2021; 12:668577.
PMID: 34290629 PMC: 8288023. DOI: 10.3389/fpsyt.2021.668577.